Skip to main content

Table 1 Hydralazine-associated anti-neutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis

From: Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report

  Short and Lockwood (1995) [[10]] Choi et al. (2000) [[1]] Yokogawa and Vivino (2009) [[9]]
Number of patients 10 10 68
Age range (years) 55–76 45–81 60–67
Females (%), female/total patients 70 (7/10) 70 (7/10) 59 (40/68)
Hydralazine dose range (mg/day) 50–150 75–200 50–300
Duration of drug exposure (months) 36–156 12–63 0.73 to >120
Patients with renal involvement 10 9 55
Patients with cutaneous involvement 4 3 25
Patients with pulmonary involvement 2 5 13
Confirmed pauci-immune GN 7 5 >25 *
ANCA-positive 10 10 45
MPO-positive 10 10 45
Anti-histone-positive (patients) NR NR (12/12)
  1. Abbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; GN, glomerulonephritis; MPO, myeloperoxidase antibodies; NR, not reported.
  2. * Authors estimated number from data available in the literature.